AIBT AIBOTICS THERAPIES, INC.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1763329 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-100.0%
TTM net income YoY-3.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-241.3%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets937.3%
Debt / equity—
Current ratio0.05x
Interest coverage-9.75x
Cash quality & payout
Operating cash flow / net income0.17x
Accruals ratio-201.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $2,183 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $2,183 | $0 | $0 |
| SG&A expense | $413,663 | $359,463 | $474,265 | $480,365 | $360,579 | $531,647 | $497,278 | $385,257 |
| Operating income | -$413,663 | -$359,463 | -$474,265 | -$480,365 | -$360,579 | -$529,464 | -$497,278 | -$385,257 |
| Interest expense | $46,917 | $58,642 | $60,555 | $11,154 | $70,070 | $61,933 | -$5,764 | $74,887 |
| Pretax income | -$536,968 | -$418,105 | -$608,284 | -$529,921 | -$486,149 | -$591,397 | -$491,514 | -$460,144 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$536,968 | -$418,105 | -$608,284 | -$529,921 | -$486,149 | -$591,397 | -$491,514 | -$460,144 |
| EBITDA | -$413,663 | -$359,463 | -$474,265 | -$480,365 | -$360,579 | -$529,215 | -$497,278 | -$385,257 |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $233,427 | $288,858 | $255,940 | $230,470 | $242,179 | $156,737 | $185,097 | $202,358 |
| Inventory | $40,525 | $40,525 | $0 | — | — | — | — | — |
| Current assets | $275,619 | $331,050 | $270,107 | $241,396 | $242,179 | $156,737 | $185,097 | $203,058 |
| PP&E, net | $0 | $0 | $0 | — | — | $0 | $0 | $0 |
| Intangibles | — | — | — | $775,547 | $943,431 | — | $1.27M | — |
| Total assets | $549,592 | $771,233 | $874,673 | $1.02M | $1.19M | $1.26M | $1.46M | $1.64M |
| Current liabilities | $5.15M | $5.05M | $4.79M | $4.90M | $5.39M | $5.10M | $4.85M | $5.00M |
| Total liabilities | $5.15M | $5.05M | $4.83M | $4.90M | $5.39M | $5.10M | $4.85M | $5.00M |
| Shareholders' equity | -$4.60M | -$4.28M | -$3.96M | -$3.89M | -$4.21M | -$3.84M | -$3.39M | -$3.36M |
| Shares outstanding | 722.51M | 539.37M | 486.90M | 318.89M | 51.63M | 45.24M | 39.99M | 5.48M |
| Cash flow statement | ||||||||
| Operating cash flow | -$47,022 | -$36,258 | -$86,604 | -$178,718 | -$164,558 | -$28,360 | -$17,261 | -$77,547 |
| Investing cash flow | $0 | $0 | — | — | $0 | $0 | — | $0 |
| Financing cash flow | -$8,409 | $69,176 | $112,074 | $167,009 | $250,000 | $0 | $0 | $0 |
| Depreciation & amortization | $0 | $0 | $0 | $0 | $0 | $249 | $0 | $0 |
| Stock-based compensation | — | — | — | — | — | — | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 34 🔒
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.